A recent study showed that CD5-CAR-modified NK92 cells can kill a variety of T cell leukemia and lymphoma cell lines as well as primary tumor cells in vitro and in xenograft mouse models of T-ALL (Chen et al., 2017). The gene discussed is CD5; the disease is acute lymphoblastic leukemia.